Inotiv, Inc. (NOTV)

In the past year, Inotiv, Inc.'s stock price has decreased significantly. Recent events impacting the stock include a preliminary Q4 and FY2025 revenue announcement, the release of Q4 and full-year financial results for fiscal 2025, an AI partnership with VUGENE, and a strategic initiative with LifeNet Health. Inotiv also received a notice of non-compliance with Nasdaq's minimum bid price listing rule. Lake Street maintained a "Buy" recommendation in December 2025, while a price target was decreased by 12% to US$4.83 around the same time.

Analysis of Inotiv, Inc. seasonal charts suggests a period of seasonal strength for the Healthcare sector, which typically runs from April 25 to December 4. For Inotiv specifically, a "Buy Date" of October 10 and a "Sell Date" of December 29 has historically resulted in positive average returns above the S&P 500 Total Return Index. Inotiv's Discovery and Safety Assessment (DSA) segment experienced strong awards and positive momentum in the first fiscal quarter of 2024, and revenue increased in Q1 fiscal 2024 compared to the prior year for research model services.

Inotiv, Inc. is a contract research organization (CRO) specializing in nonclinical and analytical drug discovery and development services for the pharmaceutical, chemical, and medical device industries. The company also sells research-quality animals and diets. Inotiv operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment focuses on drug discovery and development services, while the RMS segment is involved in the commercial production and sale of research models, lab animal diets, bedding, and bioproducts. Inotiv was founded in 1974 and rebranded in March 2021.

Inotiv, Inc. has a global presence with over 2,000 employees across more than 22 locations in North America and Europe. The company's headquarters are located in West Lafayette, Indiana, United States.

Inotiv faced criticism in 2022 for its animal testing practices, particularly concerning non-human primates and beagles. The USDA found multiple violations of the Animal Welfare Act of 1966 at the company's dog-breeding facility, and Inotiv pleaded guilty, resulting in $35 million in fines. This event is a notable part of the company's recent reputational history regarding animal welfare.

Inotiv, Inc. has a diverse ownership structure, including institutional investors, individual insiders, and retail investors. Major institutional owners include Vanguard Group Inc. and Balyasny Asset Management Llc/LP. Significant individual and insider owners include P2 Capital Partners LLC, John E. Sagartz, and Robert Leasure Jr.